Known targets — ChEMBL curated mechanism
FGFR1FGFR2FGFR3FGFR4FLT1FLT4KDRPDGFRAPDGFRB
The experimentally established mechanism targets of Ammonia Solution, Strong. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL677513 | 0.96 | — | — | |
| SCHEMBL1629376 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL27762153 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL28920266 | 0.92 | — | — | |
| Methane SCHEMBL27711976 | 0.92 | — | — | |
| Ammonia Solution, Strong SCHEMBL28067370 | 0.92 | — | — | |
| Fluoride SCHEMBL28049628 | 0.92 | — | — | |
| SCHEMBL1904 | 0.91 | — | — | |
| SCHEMBL2058760 | 0.91 | CA5A (0.46) | — | |
| SCHEMBL126970 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1399143-B1 | USE OF ACETYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION TO TREAT ANHEDONIA | SIGMA TAU IND FARMACEUTI (IT) | 2006-11-15 | — | — | EP | claimed |
| EP-1399142-B1 | USE OF ACETYL L-CARNITINE IN ASSOCIATION WITH THE BIOTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 INSULIN-RESISTANT DIABETES MELLITUS | SIGMA TAU IND FARMACEUTI (IT) | 2006-07-19 | — | — | EP | claimed |
| US-20060148896-A1 | Use of an alkanoyl L-carnitine for the preparation of a medication to treat anhedonia | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-07-06 | — | — | US | claimed |
| US-20040171685-A1 | Use of an alkanoyl l-carnitine for the preparation of a medication to treat anhedonia | SIGMA-TAU INDUSTIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-02 | — | — | US | claimed |
| US-20040152781-A1 | Use of acetyl l-carnitine for the prepartion of a medication for the preventive therapy for pain | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-08-05 | — | — | US | claimed |
| US-20040142879-A1 | Use of the acetyl l-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus | CALVANI MENOTTI (IT) | 2004-07-22 | — | — | US | claimed |
| EP-1399143-A1 | USE OF AN ALKANOYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION TO TREAT ANHEDONIA | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-03-24 | — | — | EP | claimed |
| EP-1399141-A1 | USE OF ACETYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTIVE THERAPY FOR PAIN | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-03-24 | — | — | EP | claimed |
| EP-1399142-A1 | USE OF ACETYL L-CARNITINE IN ASSOCIATION WITH THE BIOTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 INSULIN-RESISTANT DIABETES MELLITUS | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-03-24 | — | — | EP | claimed |
| WO-2002096409-A1 | USE OF ACETYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTIVE THERAPY FOR PAIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-12-05 | — | — | WO | claimed |
| WO-2002096411-A1 | USE OF AN ALKANOYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION TO TREAT ANHEDONIA | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-12-05 | — | — | WO | claimed |
| WO-2002096410-A1 | USE OF THE ACETYL L-CARNITINE IN ASSOCIATION WITH THE BIOTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 INSULIN-RESISTANT DIABETES MELLITUS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-12-05 | — | — | WO | claimed |
| US-8053472-B2 | Quantity of acetyl L-carnitine to be administered is 0.1 to 2 g/day, while the dose of biotin is 1 to 8 mg/day | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2011-11-08 | — | — | US | disclosed |
| US-20090062388-A1 | Use of acetyl L-carnitine for the preparation of a medication for the preventive therapy for pain | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-03-05 | — | — | US | disclosed |
| US-20080269307-A1 | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-30 | — | — | US | disclosed |
| EP-1399141-B1 | USE OF ACETYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTIVE THERAPY OF POST-SURGICAL PAIN | SIGMA TAU IND FARMACEUTI (IT) | 2007-09-26 | — | — | EP | disclosed |
| EP-1399143-A1 | USE OF AN ALKANOYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION TO TREAT ANHEDONIA | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002096409-A1 | USE OF ACETYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION FOR THE PREVENTIVE THERAPY FOR PAIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002096411-A1 | USE OF AN ALKANOYL L-CARNITINE FOR THE PREPARATION OF A MEDICATION TO TREAT ANHEDONIA | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002096410-A1 | USE OF THE ACETYL L-CARNITINE IN ASSOCIATION WITH THE BIOTIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 INSULIN-RESISTANT DIABETES MELLITUS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-12-05 | — | — | WO | disclosed |